View Older Stories View More Recent Stories

Jul 28, 2021 05:01PM PTC Therapeutics (PTCT) Announces Significant Improvements in Survival and Developmental Milestones Demonstrated in Type 1 SMA Patients Treated with Evrysdi
Jul 28, 2021 05:00PM Significant Improvements in Survival and Developmental Milestones Demonstrated in Type 1 SMA Patients Treated with Evrysdi™
Jun 24, 2021 08:00AM Results Add to Body of Evidence Confirming EMFLAZA®'s Benefit Over Prednisone
Jun 23, 2021 08:07AM PTC Therapeutics (PTCT) Announces Evrysdi Approved in Japan for the Treatment of Spinal Muscular Atrophy
Jun 23, 2021 08:00AM Evrysdi™ Approved in Japan for the Treatment of Spinal Muscular Atrophy
Jun 11, 2021 01:00AM Pre-symptomatic Infants with Spinal Muscular Atrophy Achieved Same Motor Milestones as Healthy Children After Treatment with Evrysdi™ in RAINBOWFISH
Jun 9, 2021 08:01AM PTC Therapeutics (PTCT) Names Mary L. Smith to Board
Jun 9, 2021 08:00AM Health and Human Services Expert Mary L. Smith Joins PTC Therapeutics' Board of Directors
May 26, 2021 08:11AM PTC Therapeutics (PTCT) Announces Orphan Drug Designations of PTC923 for the Treatment of Hyperphenylalaninemia
May 26, 2021 08:00AM PTC Therapeutics Announces Orphan Drug Designations of PTC923 for the Treatment of Hyperphenylalaninemia
May 17, 2021 08:00AM New Data Shows Devastating Impact of AADC Deficiency on Caregivers
May 4, 2021 04:01PM PTC Therapeutics Provides a Corporate Update and Reports First Quarter 2021 Financial Results
Apr 19, 2021 04:30PM PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 15, 2021 01:00AM Continued Improvements in Motor Milestones in Infants with Type 1 Spinal Muscular Atrophy After Two Years of Treatment with Evrysdi™
Apr 14, 2021 08:00AM PTC Therapeutics Launches the PTC Pinpoint Direct™ Program for Patient-Initiated Genetic Testing
Apr 7, 2021 09:30AM PTC Therapeutics Received Gallup's "Don Clifton Strengths-Based Culture" Award
Apr 7, 2021 08:50AM PTC Therapeutics to Host PTC518 Huntington Disease Deep Dive Webinar
Apr 1, 2021 08:00AM PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™
Mar 30, 2021 01:00AM PTC Therapeutics Announces the European Approval of Evrysdi™ for the Treatment of Spinal Muscular Atrophy
Mar 16, 2021 06:21AM PTC Therapeutics (PTCT) Announces Results from the Second Year of Evrysdi Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA Patients
Mar 16, 2021 02:00AM Results from the Second Year of Evrysdi™ (risdiplam) Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA Patients
Mar 15, 2021 08:00AM PTC Presents Results from a Real-World Study of Steroid Switching in the Treatment of Patients with Dystrophinopathies
Mar 9, 2021 08:00AM Spinal Muscular Atrophy (SMA) Foundation and PTC Therapeutics Expand Partnership to Advance Drug Discovery and Development Research in Regenerative Medicine
Feb 26, 2021 06:42AM PTC Therapeutics (PTCT) Announces CHMP Adopts Positive Opinion for Evrysdi for Treatment of SMA in Adults and Children Aged Two Months and Older
Feb 26, 2021 06:40AM CHMP Adopts Positive Opinion for Evrysdi™ for the Treatment of Spinal Muscular Atrophy in Adults and Children Aged Two Months and Older
Feb 25, 2021 04:02PM PTC Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
Feb 17, 2021 08:09AM PTC Therapeutics (PTCT) Begins Second Stage of FITE19 Phase 2/3 Clinical Trial Evaluating PTC299 for Treatment of COVID-19
Feb 17, 2021 08:00AM PTC Therapeutics Reports the Initiation of the Second Stage of the FITE19 Phase 2/3 Clinical Trial Evaluating PTC299 for the Treatment of COVID-19
Jan 14, 2021 08:00AM PTC Therapeutics Opens Applications for the Annual STRIVE Awards Program and Introduces a New Award Category
Dec 4, 2020 08:00AM PTC Announces Translarna™ Approval in Russia for the Treatment of Duchenne Muscular Dystrophy
Nov 30, 2020 08:09AM PTC Therapeutics (PTCT) Reports Initiation of Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia
Nov 30, 2020 08:00AM PTC Therapeutics Announces Initiation of Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia
Nov 17, 2020 08:04AM PTC Therapeutics (PTCT) Announces that PTC518 Has Entered into a Phase 1 Clinical Trial for the Huntington's Disease Program
Nov 17, 2020 08:00AM PTC Therapeutics Announces that PTC518 Has Entered into a Phase 1 Clinical Trial for the Huntington's Disease Program
Nov 16, 2020 08:00AM PTC Therapeutics Highlights Data on High Disease Burden and Value of Treatment Across Two Rare Diseases
Oct 29, 2020 04:01PM PTC Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
Oct 26, 2020 08:00AM PTC Therapeutics Announces Initiation of a Registration-Directed Clinical Trial to Evaluate Vatiquinone in Mitochondrial Epilepsy
Oct 21, 2020 08:34AM PTC Therapeutics (PTCT) Says Evrysdi Continues to Make Global Progress for the Treatment of Spinal Muscular Atrophy
Oct 21, 2020 08:33AM Evrysdi™ (risdiplam) Continues to Make Global Progress for the Treatment of Spinal Muscular Atrophy
Sep 28, 2020 06:27AM PTC Therapeutics (PTCT) Two-Year Data of Evrysdi in Infants with Spinal Muscular Atrophy Demonstrate Continued Improvement of Developmental Milestones
Sep 28, 2020 01:00AM Two-Year Data of Evrysdi™ (risdiplam) in Infants with Spinal Muscular Atrophy Demonstrate Continued Improvement of Developmental Milestones
Sep 9, 2020 08:00AM PTC Therapeutics Launches PTC PINPOINT - A Genetic Testing Program for Individuals Suspected of Having Neurotransmitter Disorders
Sep 8, 2020 08:00AM PTC Therapeutics' 2020 STRIVE Awards for Duchenne Muscular Dystrophy Recognize Four Patient Advocacy Organizations
Aug 26, 2020 08:01AM PTC Therapeutics (PTCT) Reports $20M Milestone Payment Following U.S. FDA Approval of Evrysdi (risdiplam)
Aug 26, 2020 08:00AM PTC Therapeutics Announces First Commercial Milestone Payment Following U.S. FDA Approval of Evrysdi™ (risdiplam)
Aug 17, 2020 08:04AM PTC Therapeutics (PTCT) Announces Acceptance of the European MAA for Evrysdi for Treatment of Spinal Muscular Atrophy
Aug 17, 2020 08:00AM PTC Announces the Acceptance of the European Marketing Authorization Application for Evrysdi™ (risdiplam) for the Treatment of Spinal Muscular Atrophy
Aug 7, 2020 02:21PM PTC Therapeutics (PTCT) Announces FDA Approval of Evrysdi for Spinal Muscular Atrophy in Adults and Children 2 months and older
Aug 7, 2020 01:54PM PTC Therapeutics Announces FDA Approval of Evrysdi™ (risdiplam) for the Treatment of Spinal Muscular Atrophy in Adults and Children 2 months and older
Aug 6, 2020 08:00AM PTC Therapeutics' Mary Frances Harmon Named One of the Most Inspiring Leaders in Life Sciences by PharmaVOICE Magazine
View More Recent Stories View Older Stories